Hematological conditions can lead to serious disturbances in blood rheology, being frequently associated with increased systemic inflammation and increased risk of bleeding. The imbalance between coagulation and thrombolytic factors in patients with acute coronary syndromes may lead to undesirable outcomes, and the success of emergency coronary angioplasty or by-pass grafting may be altered by increased bleeding in coagulopathies such as hemophilia. This paper intends to review the present knowledge in the field of acute coronary syndromes in subjects with hematological and onco-hematological disorders such as thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura, von Willebrand disease, hemophilia, polycythemia vera, erythrocyte disorders, myelodysplastic syndrome, leukemia, lymphoma or myeloma.
INTRODUCTION
Hematological conditions can lead to serious disturbance in the blood rheology resulting at times in a pro-thrombotic status. The diseases in this group are frequently associated with an increased systemic inflammation and an increased risk of bleeding, resulting in an imbalance between coagulation and thrombolytic factors.
Various changes in blood homeostasis associated with the occurrence of an acute coronary syndrome may lead to undesirable outcomes and the success of emergency coronary angioplasty or bypass grafting may be altered by increased bleeding in coagulopathies such as hemophilia.
This paper intends to review present knowledge in the field of acute coronary syndromes in subjects with hematological and onco-hematological disorders.
THE LINk BETwEEN ACUTE CORONARY SYNDROmES, PLATELET DISORDERS AND COAgULOPATHIES
Acute coronAry syndromes in pAtients with thrombocytopeniA And thrombotic thrombocytopenic purpurA
Platelets have a significant role in the development of acute coronary thrombosis that overlaps a ruptured atherosclerotic plaque. Immune thrombocytopenic purpura (ITP), leading to a low platelet count, is rarely associated with ACS. Despite the increased risk of bleeding, patients with ITP also have an increased rate of atherosclerosis and thrombosis. years, and 15 cases of ITP with PCI, mean age 62 ± 16 years.
Their conclusion was that both revascularization methods are safe and feasible and that the cessation of antiplatelet therapy should be commenced when the platelet count is less than 20,000/μL. Willebrand disease, describing ten cases of ACS. Their results showed that in subjects with mild congenital hemorrhagic disease, the intervention was not complicated by severe hemorrhagic events even if they had not received factor concentrates before the coronarography.
The administration of double antiplatelet treatment for a short amount of time was tolerated relatively well. Patients who received aspirin for a long-term, had shown mild bleeding complications, but these cases require close follow-up.
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In a case report (2013) on type 1 von Willebrand disease, with 25% factor VIII activity, a percutaneous coronary intervention was performed with bare-metal stent implantation and dual-antiplatelet therapy was administered for two weeks, without any bleeding complications. weeks from its introduction in the therapeutic plan.
In case of STEMI in patients with hemophilia, primary PCI is recommended. Bare-metal stents are preferred to drug-eluting stents due to the fact that they require a smaller amount of time for two antiplatelet drugs, usually one month, and consequently, a shorter time of rigorous prophylaxis maintaining the factor concentration at 30% or more. Initial management of STEMI with glycoprotein IIb/IIIa inhibitors is not feasible due to an enhanced bleeding risk. In hemophilic patients, the activity of the missing factor should be at least 80% at the moment of heparin administration and coronary intervention.
16-18
The ARCHER study (2015) analyzed the frequency of cardiovascular disease in hemophilic patients, and reported an incidence of 14/1000 patients for any CVD event, From the 2,000 hemophiliacs, 20 had presented an ACS.
They concluded that ACS occurs in younger hemophilia patients who have associated cardiovascular risk factors, and that secondary cardiovascular prevention and revascularization therapies followed by dual antiplatelet therapy are feasible therapeutic approaches in selected cases.
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Acs in subjects with polycythemiA VerA
And essentiAl thrombocythemiA
Polycythemia vera (PV) is defined as the excessive proliferation of red blood cells, leading to hyperviscosity and increased risk of thrombosis. In patients with PV, the main causes of mortality are acute myocardial infarction and heart failure.
Essential thrombocythemia (ET) is manifested clinical-
ly as the excessive production of platelets. These platelets are dysfunctional, leading to an increased risk of bleeding and thrombosis. Thromboembolic events are frequent and are usually represented by deep vein thrombosis and pulmonary embolism. AMI is unusual in this case.
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According to the ECLAP study, the prevention of acute coronary syndromes in PV patients consists of low-dose aspirin for the prevention of thromboembolic events that reduces the risk of nonfatal myocardial infarction by 30%. 23 Cytoreductive therapy aims to reduce thromboembolic risk by using phlebotomy or hydroxyurea and is recommended for all patients in order to achieve the optimal control of blood cell counts.
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In patients with PV and ET with acute myocardial infarction, percutaneous reperfusion followed by aggressive antithrombotic treatment is recommended in association with cytoreductive medication. Cytoreductive treatment is linked to an important decrease in the rate of thrombotic complications. Hydroxyurea is suggested as first-line treatment and anagrelide is recommended as a secondline therapy due to its minimal leukemogenic effects in young patients.
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De Stefano et al. studied the recurrence rate of thrombotic events in patients with PV/TH who had previously suffered arterial or venous thrombosis or both, in a retrospective multicenter study that included 497 patients.
Their results showed a 33.6% thrombosis recurrence rate and pointed out an elevated leukocyte count as a risk factor for recurrence in patients older than 60 years. This study also showed that the best preventive strategy in these cases is represented by cytoreductive therapy associated with antiplatelet drugs and anticoagulants.
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A meta-analysis on 17 studies that included 2,905 patients showed that the presence of the JAK2 V617F mutation was associated with an increased risk of both venous and arterial thrombosis in patients with essential thrombocythemia.
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Similar results were published in a retrospective multicenter study involving 239 patients with ET. In that study, previous thrombotic history and the JAK2 V617F mutation were connected to an increased 10-year cumulative rate of thrombohemorrhagic events. 
30,31
In one of the above mentioned cases, the patient presented with STEMI and had undergone coronary stenting. Aplastic anemia is caused by bone marrow failure that leads to a decreased blood cell count on several lines. Acute coronary events in patients with aplastic anemia have a very low incidence, but there are a few cases cited in the literature.
A case of a 52-year-old patient with aplastic anemia with late stent thrombosis has been published in 2012 by
Shin et al. 40 The patient had undergone PCI with stent angioplasty on the left anterior descending artery one year before presentation. At presentation, the platelet count was 12,000/µL, for which the patient had received platelet transfusion resulting in acute stent thrombosis. This case illustrates the increased risk correlated with platelet transfusion in patients with coronary stenting. Their results suggested that Hodgkin lymphoma patients had a more increased risk of AMI compared to the general population, and that the relative risk of death from MI was more than two-fold higher (RR: 2.1, 95% CI 2.5-2.9).
Within the first year after the initiation of therapy, the myocardial infarction mortality rate increased four-fold.
From year one to year fourteen after treatment initiation, the relative risk of death was increased two-fold, from were fatal. They concluded that the incidence of cardiovascular disease and cardiac procedures is higher 10 years or more after RT, thus suggesting that the effectiveness of screening for CVD is limited before 10 years following initial treatment for Hodgkin lymphoma. given RT alone, 5% chemotherapy (CT) alone, 38% RT to the general population. The incidence of MI was significantly higher after 10 years following treatment. However, there were no significant differences in the rate of MI, angina pectoris and congestive heart failure between different treatment regimens. 
62,63
A case report (2010) highlighted the relationship between bortezomib treatment and ischemic heart disease.
A 79-year-old patient diagnosed with MM, without any history of cardiovascular disease, presented with acute myocardial infarction during treatment with bortezomib.
The patient underwent emergency coronary angioplasty with stent implantation and continued with the course of chemotherapy. Five days later the patient developed chest pain due to coronary spasm, which is a side effect of bortezomib therapy, due to endothelial dysfunction and impairment of nitric oxide production.
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CONCLUSIONS
Patients with previously diagnosed hematological disorders are at an increased risk for acute coronary syndromes, with a higher risk of thrombosis or bleeding, depending on the underlying hemopathy. Leukemia and myelodysplastic syndrome lead to an increased inflammatory status that causes coronary plaque disruption and infiltration of the vessel wall, leading to acute thrombosis and myocardial infarction. On the other hand, the presence of blood clotting disorders, including thrombopathies, thrombocytopenia and conditions that impair various coagulation factors, can lead to a high hemorrhagic risk, thus affecting the outcome of patients that undergo percutaneous coronary interventions or coronary artery bypass grafting.
Furthermore, patients with a high hemorrhagic risk due to blood clotting disorders should receive bare-metal stents that require a shorter period of dual antiplatelet treatment.
Multiple myeloma leads to a pro-thrombotic state that causes both arterial and venous thrombosis. Paroxysmal nocturnal hemoglobinuria leads to a high risk of thrombosis that may lead to acute coronary events. Patients with lymphoma present a late risk of developing cardiovascular disease due to radiotherapy and chemotherapy, therefore an efficient control of the cardiovascular risk factors might lead to a risk reduction.
